Improvement in dissolution of liver fibrosis in an animal model by tetrathiomolybdate

Experimental Biology and Medicine

Volumn 234, Issue 6, 2009, Pages 662-665

  Hou, Guoqing ^a   Dick, Robert ^a   Brewer, George J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Anticopper therapy; Carbon tetrachloride liver injury; Ceruloplasmin; Hydroxyproline; Therapy of liver fibrosis

Indexed keywords

CARBON TETRACHLORIDE; HYDROXYPROLINE; TETRATHIOMOLYBDIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATALYSIS; CONTROL GROUP; CONTROLLED STUDY; DISEASE MODEL; DISSOLUTION; FEMALE; LIVER FIBROSIS; MOUSE; NONHUMAN; TREATMENT DURATION;

ANIMALS; CARBON TETRACHLORIDE; CARBON TETRACHLORIDE POISONING; COPPER; FEMALE; HEPATOLENTICULAR DEGENERATION; HUMANS; LIVER CIRRHOSIS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MOLYBDENUM; TIME FACTORS;

ANIMALIA; MUS;

EID: 66449100034     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.3181/0811-RM-319     Document Type: Article

References (23)

1. Marcellini M, Di Ciommo V, Callea F, Devito R, Comparcola D, Sartorelli MR, Carelli G, Nobili V. Treatment of Wilson's disease with zinc from the time of diagnosis in pediatric patients: a single-hospital, 10-year follow-up study. J Lab Clin Med 145:139-143, 2005. (Pubitemid 40432363)
2. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 331:1286-1292, 1994. (Pubitemid 24333194)
3. Brewer GJ, Ullenbruch MR, Dick RB, Olivarez L, Phan SH. Tetrathiomolybdate therapy protects against bleomycin-induced pulmonary fibrosis in mice. J Lab Clin Med 141:210-216, 2003. (Pubitemid 36324239)
4. Brewer GJ, Dick R, Ullenbruch MR, Jin H, Phan SH. Inhibition of key cytokines by tetrathiomolybdate in the bleomycin model of pulmonary fibrosis. J Inorg Biochem 98:2160-2167, 2004. (Pubitemid 39488145)
5. Askari FK, Dick RB, Mao M, Brewer GJ. Tetrathiomolybdate therapy protects against concanavalin A and carbon tetrachloride hepatic damage in mice. Exp Bio Med 229:857-863, 2004. (Pubitemid 39166492)
6. Song M, Song Z, Barve S, Zhang J, Chen T, Liu T, Arteel GE, Brewer GJ, McClain CJ. Tetrathiomolybdate protects against bile duct ligation-induced cholestatic liver injury and fibrosis. J Pharmacol Exp Ther 325:409-416, 2008.
7. Brewer GJ, Dick RD, Yuzbasiyan-Gurkan V, Tankanow R, Young AB, Kluin KJ. Initial therapy of patients with Wilson's disease with tetrathiomolybdate. Arch Neurol 48:42-47, 1991.
8. Linder MC, Houle PA, Isaacs E, Moor JR, Scott LE. Copper regulation of ceruloplasmin in copper-deficient rats. Enzyme 24:23-35, 1979. (Pubitemid 9104724)
9. Sunderman FW Jr, Nomoto S. Measurement of human serum ceruloplasmin by its p-phenylenediamine oxidase activity. Clin Chem 16:903-910, 1970.
10. Brewer GJ, Dick RD, Johnson V, Wang Y, Yuzbasiyan-Gurkan V, Kluin K, Fink JK, Aisen A. Treatment of Wilson's disease with ammonium tetrathiomolybdate. I. Initial therapy in 17 neurologically affected patients. Arch Neurol 51:545-554, 1994.
11. Brewer GJ, Johnson V, Dick RD, Kluin KJ, Fink JK, Brunberg JA. Treatment of Wilson disease with ammonium tetrathiomolybdate. II. Initial therapy in 33 neurologically affected patients and follow-up with zinc therapy. Arch Neurol 53:1017-1025, 1996.
12. Brewer GJ, Hedera P, Kluin KJ, Carlson M, Askari F, Dick RB, Sitterly J, Fink JK. Treatment of Wilson disease with ammonium tetrathiomolybdate. III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy. Arch Neurol 60:379-385, 2003.
13. Brewer GJ, Askari F, Lorincz MT, Carlson M, Schilsky M, Kluin KJ, Hedera P, Moretti P, Fink JK, Tankanow R, Dick RB, Sitterly J. Treatment of Wilson disease with ammonium tetrathiomolybdate. IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Arch Neurol 63:521-527, 2006.
14. McQuaid A, Mason J. A comparison of the effects of penicillamine, trientine, and trithiomolybdate on [35S]-labeled metallothionein in vitro; implications for Wilson's disease therapy. J Inorg Biochem 41:87-92, 1991.
15. Mills CF, El-Gallad TT, Bremner I. Effects of molybdate, sulfide, and tetrathiomolybdate on copper metabolism in rats. J Inorg Biochem 14:189-207, 1981. (Pubitemid 11063055)
16. Bremner I, Mills CF, Young BW. Copper metabolism in rats given dior trithiomolybdates. J Inorg Biochem 16:109-119, 1982.
17. Mills CF, El-Gallad TT, Bremner I, Weham G. Copper and molybdenum absorption by rats given ammonium tetrathiomolybdate. J Inorg Biochem 14:163-175, 1981. (Pubitemid 11120306)
18. Gooneratne SR, Howell JM, Gawthorne JM. An investigation of the effects of intravenous administration of thiomolybdate on copper metabolism in chronic Cu-poisoned sheep. Br J Nutr 46:469-480, 1981. (Pubitemid 12213841)
19. Ma S, Hou G, Dick RD, Brewer GJ. Tetrathiomolybdate protects against liver injury from acetaminophen in mice. J Appl Res Clin Exp Ther 4:419-426, 2004. (Pubitemid 39299386)
20. Hou G, Dick R, Abrams GD, Brewer GJ. Tetrathiomolybdate protects against cardiac damage by doxorubicin in mice. J Lab Clin Med 146:299-303, 2005. (Pubitemid 41464407)
21. McCubbin MD, Hou G, Abrams GD, Dick R, Zhang Z, Brewer GJ. Tetrathiomolybdate is effective in a mouse model of arthritis. J Rheumatol 33:2501-2506, 2006. (Pubitemid 46067832)
22. Hou G, Abrams G, Dick R, Brewer GJ. Efficacy of tetrathiomolybdate in a mouse model of multiple sclerosis. Transl Res 152:239-244, 2008.
23. Brewer GJ, Dick R, Zeng C, Hou G. The use of tetrathiomolybdate in treating fibrotic, inflammatory, and autoimmune diseases, including the non-obese diabetic mouse model. J Inorg Biochem 100:927-930, 2006.